Trial Profile
A Phase II Study of NK012 in Sensitive Relapsed and Refractory Relapsed Small-Cell Lung Cancer (SCLC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs NK 012 (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Nippon Kayaku
- 24 Jun 2011 Planned End Date changed from 1 Feb 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 24 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Nov 2010 Planned End Date changed from 1 Sep 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.